Invesco Pharmaceuticals ETF Offers Lower Drawdown and Higher Yield Than Biotech ETF
IVZ•Invesco Pharmaceuticals ETF holds 30 securities versus 155 in the State Street SPDR S&P Biotech ETF and has limited its five-year max drawdown to 17.5% compared with 54% for the biotech fund. The ETF also delivers a higher dividend yield alongside a lower five-year beta, which may attract AUM inflows and boost IVZ’s fee income.
1. ETF Structure and Performance
Invesco Pharmaceuticals ETF comprises 30 securities and has recorded a five-year beta below that of the broad biotech market fund. Its max drawdown over the same period was 17.5%, significantly outperforming the State Street SPDR S&P Biotech ETF, which contains 155 holdings and faced a 54% peak-to-trough decline.
2. Yield Advantage and Investor Appeal
Alongside risk mitigation, the Invesco ETF offers a higher trailing dividend yield than its biotech peer, enhancing its appeal to income-focused investors. Improved yield and lower volatility could drive net asset inflows, potentially lifting management fee revenue for Invesco Ltd.
